PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients-Reference-Cited by-同舟云学术

PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients

Published:2015-05-07 Issue:6 Volume:75 Page:1289-1301
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Koumarianou Anna,Karayannopoulou Georgia,Gourgioti Georgia,Batistatou Anna,Bobos Mattheos,Efstratiou Ioannis,Miliaras Dimosthenis,Galani Eleni,Pentheroudakis George,Pectasides Dimitrios,Aravantinos Gerasimos,Bafaloukos Dimitrios,Papakostas Pavlos,Razis Evangelia,Kalofonos Haralabos P.,Petraki Kalliopi,Sotiropoulou Maria,Kalogeras Konstantine T.,Fountzilas George

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-015-2762-3.pdf

Reference39 articles.

1. Slamon DJ, Clark GM (1988) Amplification of c-erbB-2 and aggressive human breast tumors? Science 240(4860):1795–1798

2. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17(9):2639–2648

3. Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, Slamon DJ (2000) Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 18(21):3651–3664

4. Paik S, Kim C, Wolmark N (2008) HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 358(13):1409–1411. doi: 10.1056/NEJMc0801440

5. Perez EA, Reinholz MM, Hillman DW, Tenner KS, Schroeder MJ, Davidson NE, Martino S, Sledge GW, Harris LN, Gralow JR, Dueck AC, Ketterling RP, Ingle JN, Lingle WL, Kaufman PA, Visscher DW, Jenkins RB (2010) HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol 28(28):4307–4315. doi: 10.1200/JCO.2009.26.2154

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. mRNA expression of specific HER ligands and their association with clinical outcome in patients with metastatic breast cancer treated with trastuzumab;Oncology Letters;2021-11-17

2. Prognostic Impact of Src, CDKN1B, and JAK2 Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab;Translational Oncology;2019-05

3. Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study;PLOS ONE;2018-12-06

4. Circulating HER‑2 mRNA in the peripheral blood as a potential diagnostic and prognostic biomarker in females with breast cancer;Oncology Letters;2018-07-05

5. Evaluation of the Insulin-like Growth Factor Receptor Pathway in Patients with Advanced Breast Cancer Treated with Trastuzumab;Cancer Genomics - Proteomics;2018